This renal symposium provided an overview of diverse but key areas of nephrology. Topics included the molecular basis of the glomerular filtration barrier; the clinical management of the nephrotic syndrome; the association of CKD with cardiovascular morbidity; the link between hyperuricaemia, obesity and cardiovascular disease; current immunosuppressive therapies; long-term morbidity and mortality issues in transplant recipients; electrolyte disorders; and conservative therapy for renal failure.
Get full access to this article
View all access options for this article.
References
1.
EreminaVSCuiGerberH Vascular endothelial growth factor A signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17:724–735.
2.
GrossMLWHankeAKochHZiebartKAmannRitzE. Intraperitoneal protein injection in the axolotl: The amphibian kidney as a novel model to study tubulointerstitial activation. Kidney Int 2002; 62:51–59.
3.
AriciMRChanaALewingtonJBrownBrunskillNJ.Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated receptor-?. J Am Soc Nephrol 2003; 14:17–27.
4.
SidawayJERGDavidsonMcTaggartF Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptormediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004; 15:2258–2265.
5.
ChanaRBrunskillN. Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma. Am J Nephrol 2006; 26:67–74.
6.
DeschenesGEFerailleDoucetA. Mechanisms of oedema in nephrotic syndrome: old theories and new ideas. Nephrol Dial Transplant 2003; 18:454–456.
7.
BenetosACAdamopoulosBureauJ-M Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002; 105:1202–1207.
8.
SafarMEJBlacherPannierB Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39:735–738.
9.
McEnieryCMMSchmittQasemA Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44:305–310.
10.
CovicADGoldsmithPGusbeth-TatomirIBuhaescuCovicM. Successful renal transplantation decreases aortic stiffness and increases vascular reactivity in dialysis patients. Transplantation 2003; 76:1573–7.
11.
FeigDIMMazzaliKangD-H Serum uric acid: A risk factor and a target for treatment? J Am Soc Nephrol 2006; 17:S69–73.
12.
WatanabeSD-HKangFengL Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40:355–360.
13.
Johnson R,Titte S, Cade J, Rideout B, Oliver W. Uric acid, evolution and primitive cultures. Semin Nephrol 2005; 25:3–8.
14.
PirschJJMillerMDeierhoi,Vincenti F, Filo R. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63:977–83.
15.
The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61:1029–37.
16.
KahanBD.Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356:194–202.
17.
NashanBRMoorePAmlotA-GSchmidtKAbeywickramaSoulillouJ-P.Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350:1193–1198.
18.
HariharanSMAMcbrideWSCherikh,Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62:311–318.
19.
JohnsonRHKreisROberbauerCBrattstromKClaessonErisJ. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777–86.
20.
BorrowsRMLoucaidouTrompJV Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 2004; 4:1845–51.
21.
TanHPDJKaczorowskiBasuA Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6:2409–2417.
22.
NankivellBJRJBorrowsCL-SFungPJO'ConnellRDMAllenChapmanJR.The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326–2333.
23.
DudleyCEPohankaRiadH Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction:The ‘creeping creatinine’ study. Transplantation 2005; 79:466–75.
24.
HoldaasHBFellstromJardineAG Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361:2024–2031.
25.
KauffmanHMWSCherikhMAMcBrideYChengHantoDW.Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transplant International 2006; 19:607–620.
26.
SmithCMDSilva-GaneSChandna,Warwicker P, Greenwood R, Farrington K. Choosing not to dialyse: evaluation of planned nondialytic management in a cohort of patients with end-stage renal failure. Nephron Clinical Practice 2003; 95:40–46.
